The Association of the British Pharmaceutical Industry (ABPI) Code of Practice sets standards for the pharmaceutical industry in the UK, ensuring transparency and ethical engagement with patients, the public, and healthcare professionals.
Under the disclosure requirements, pharmaceutical companies must openly report certain payments and benefits provided to individuals and organisations. For patients, the public, and members of the public (MOP), this means that any payments made for participation in research, interviews, advisory boards, or other engagements must be disclosed in a transparent manner. This ensures accountability and maintains public trust in industry practices.
Syner-Med (Pharmaceutical Products) Ltd 2024 Disclosures for Members of the Public including Patients and Journalists.
Patients
In accordance with the ABPI (Association of the British Pharmaceutical Industry) disclosure regulations, we wish to inform visitors that payments were made to patients who participated in interviews regarding their experiences living with recurrent Urinary Tract Infections (r-UTI).These interviews were conducted to help our marketing team gain a deeper understanding of the patient journey and experiences in managing this condition. The insights gathered aim to enhance awareness and support for individuals affected by r-UTI. The ABPI recommends using an optional template to disclose such information, please see attached file.
- Number: 9
- Fees:£60.00 per patient, total payment £540.00
- Out of pocket expenses 0
Members of the Public
- Number: 0
- Fees: NA
Journalists
- Number: 0
- Fees: NA
Policy
Disclosures
Privacy Policy
Cookie Policy
Data Protection Policy
Slavery & Human Trafficking Statement
Privacy Policy
Cookie Policy
Data Protection Policy
Slavery & Human Trafficking Statement
Syner-Med publicly discloses information about its clinical trials in external public registries, such as EU Clinical Trials Register via https://www.clinicaltrialsregister.eu
